Tarsus Pharmaceuticals Inc (TARS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2025 | 06-2025 | 03-2025 | 12-2024 | 09-2024 | |
| Sales | 118,697 | 102,660 | 78,335 | 66,408 | 48,118 |
| Cost of Goods | 8,309 | 6,237 | 5,211 | 4,926 | 3,242 |
| Gross Profit | 110,388 | 96,423 | 73,124 | 61,482 | 44,876 |
| Operating Expenses | 125,226 | 118,844 | 99,615 | 86,829 | 70,280 |
| Operating Income | -14,529 | -22,184 | -26,280 | -24,421 | -25,162 |
| Interest Expense | 2,268 | 2,240 | 2,213 | 2,312 | 2,445 |
| Other Income | 4,212 | 4,084 | 3,373 | 3,620 | 4,187 |
| Pre-tax Income | -12,585 | -20,340 | -25,120 | -23,113 | -23,420 |
| Net Income Continuous | -12,585 | -20,340 | -25,120 | -23,113 | -23,420 |
| Net Income | $-12,585 | $-20,340 | $-25,120 | $-23,113 | $-23,420 |
| EPS Basic Total Ops | -0.30 | -0.48 | -0.64 | -0.57 | -0.61 |
| EPS Basic Continuous Ops | -0.30 | -0.48 | -0.64 | -0.57 | -0.61 |
| EPS Diluted Total Ops | -0.30 | -0.48 | -0.64 | -0.57 | -0.61 |
| EPS Diluted Continuous Ops | -0.30 | -0.48 | -0.64 | -0.57 | -0.61 |
| EPS Diluted Before Non-Recurring Items | -0.30 | -0.48 | -0.64 | -0.60 | -0.61 |
| EBITDA(a) | $-15,451 | $-23,294 | $-26,995 | $-25,332 | $-25,893 |